ArticleJournal of medicinal chemistry2025

Discovery of STX-721, a Covalent, Potent, and Highly Mutant-Selective EGFR/HER2 Exon20 Insertion Inhibitor for the Treatment of Non-Small Cell Lung Cancer.

Benjamin C Milgram et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.